Exploring immune responses in Hodgkin's lymphoma patients treated with pembrolizumab

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study focuses on patients with relapsed or refractory classic Hodgkin Lymphoma who are being treated with pembrolizumab at the IRCCS AOU of Bologna. It involves collecting peripheral blood samples from participants before and during their treatment to analyze the immunological senescence phenotype. The study aims to understand how these immune characteristics may influence treatment resistance and patient outcomes. The findings could provide insights into optimizing therapy for Hodgkin's lymphoma patients.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients of both sexes aged ≥ 18 years at enrollment
* Patients affected by cHL R/R candidate to receive a treatment with Pembrolizumab
* Signature of informed consent

Exclusion Criteria:

* none

Where it's running

• IRCCS Azienda Ospedaliero - Universitaria di Bologna
  Bologna, Italy Recruiting

Study contacts

• Principal investigator: Pier Luigi Zinzani, MD — IRCCS Azienda Ospedaliero-Universitaria di Bologna
• Study coordinator: Pier Luigi Zinzani, MD
• Email: pierluigi.zinzani@unibo.it
• Phone: +390512144042

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Comparing new drugs to standard treatment for relapsed Hodgkin lymphoma

  This study is testing if new drugs Pembrolizumab and Brentuximab vedotin work better than standard treatment for people with relapsed Hodgkin lymphoma.

  Recruiting at 18 sites Phase 2 Canadian Cancer Trials Group · Concord, New South Wales and 17 other locations · NCT05180097

• Testing pembrolizumab with GVD for relapsed Hodgkin lymphoma

  This study is testing if combining the immunotherapy drug pembrolizumab with GVD can help people with relapsed Hodgkin lymphoma feel better after their previous treatments.

  Recruiting at 10 sites Phase 2 Memorial Sloan Kettering Cancer Center · Duarte, California and 9 other locations · NCT03618550

• Lenvatinib and Pembrolizumab With or Without SBRT for Metastatic Kidney Cancer

  This study tests whether adding SBRT to standard lenvatinib plus pembrolizumab helps people with metastatic kidney cancer who have stable disease after initial treatment.

  Recruiting at 8 sites Phase 2 Kidney Cancer Research Bureau · Kazan' and 7 other locations · NCT07928167

• Bladder cancer: test a biomarker-guided plan after neoadjuvant therapy

  This phase 2 study tests a biomarker- and response-guided plan to preserve the bladder in patients with muscle-invasive bladder cancer after neoadjuvant therapy.

  Recruiting Phase 2 Fox Chase Cancer Center · Philadelphia, Pennsylvania · NCT07908979

• Peripheral neuropathy during perioperative therapy with enfortumab vedotin and pembrolizumab in muscle-invasive urothelial cancer

  This study follows adults with muscle-invasive urothelial cancer to see how nerve-related side effects develop when people receive enfortumab vedotin and pembrolizumab around surgery as part of standard care.

  Recruiting at 3 sites Comprehensive Cancer Center Munich (CCCM) · Munich, Bavaria and 2 other locations · NCT07870577

• Sacituzumab Tirumotecan plus Pembrolizumab in advanced biliary tract cancer

  This study tests whether the combination of Sacituzumab Tirumotecan and Pembrolizumab can help people with advanced biliary tract cancer who have already had at least one approved therapy fail.

  Recruiting Phase 2 Peking Union Medical College Hospital · Beijing, Beijing Municipality · NCT07850791

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.